2,944,771.0
New Delhi: The proportion of adverse events following immunisation (AEFIs) by Covishield has exceeded that for Covaxin, according to health ministry data. However, these have been minor for both and should put to rest any doubts about their safety, health officials and experts said.
India’s Covid-19 vaccine programme began on January 16 and has so far covered about 6.8 million people.
AEFIs for Covishield, made by Serum Institute of India (SII) and based on AstraZeneca-Oxford University technology numbered 8,402 or 0.192% of jabs, according to all-India data collated by the ministry of health and family welfare until February 4. Adverse events after administering Bharat Biotech’s Covaxin numbered 81 or 0.096%, it said.